期刊
BLOOD
卷 122, 期 14, 页码 2433-2442出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2012-12-472183
关键词
-
类别
资金
- DFG (German Research Foundation)
- Deutsche Krebshilfe
- Wilhelm-Sander-Stiftung
- German Jose Carreras Foundation
- National Institutes of Health [CA118316]
The transcription factor CCAAT enhancer binding protein alpha (C/EBP alpha) is a master regulator in granulopoiesis and is frequently disrupted in acute myeloid leukemia (AML). We have previously shown that C/EBP alpha exerts its effects by regulating microRNAs (miRs) such as miR-223 and miR-34a. Here, we confirm miR-30c as a novel important target of C/EBP alpha during granulopoiesis. Thus, wild-type C/EBP alpha-p42 directly upregulates miR-30c expression, whereas C/EBP alpha-p30, found in AML, does not. miR-30c is downregulated in AML, especially in normal karyotype AML patients with CEBPA mutations. An induced C/EBP alpha knockout in mice leads to a significant downregulation of miR-30c expression in bone marrow cells. We identified NOTCH1 as a direct target of miR-30c. Finally, a block of miR30c prevents C/EBP alpha-induced downregulation of Notch1 protein and leads to a reduced CD11b expression in myeloid differentiation. Our study presents the first evidence that C/EBP alpha, miR-30c, and Notch1 together play a critical role in granulocytic differentiation and AML, and particularly in AML with CEBPA mutations. These data reveal the importance of deregulated miRNA expression in leukemia and may provide novel biomarkers and therapeutic targets in AML.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据